Filippo Torrisi

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

1 INTRODUCTION Glioblastoma (GBM) is the most aggressive primary malignant brain tumour affecting the adult population, with a prognosis that remains dramatically poor and about the 5% of patients survive 5 years after diagnosis.1 GBM heterogeneity limits the efficacy of the current therapeutic approaches including surgical resection, followed by radiotherapy (RT) and temozolomide chemotherapy.2 Therefore, developing new therapeutic strategies and revealing the mechanisms responsible for the...